Skip to content

Evaluation for the risk of allergy to COVID-19 vaccines in people with history of allergy diathesis.

Evaluation for the risk of allergy to COVID-19 vaccines in people with history of allergy diathesis.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2021/09/036832
Enrollment
100
Registered
2021-09-24
Start date
Unknown
Completion date
Unknown
Last updated
2022-11-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: T784- Other and unspecified allergy

Interventions

Intervention1: Skin test (Skin prick test and intradermal test) for the assessment of allergic response to COVISHIELD vaccine, Polysorbate 80 and PEG (Poly ethylene glycol).: Skin test (Skin prick tes

Sponsors

ICMR
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Participants with history of anaphylaxis or allergic reaction or any allergies. Participants who are yet unvaccinated to COVID-19 vaccine OR Participants who have taken the first dose of COVID-19 vaccine, due for the second dose OR Participants who have taken second dose of COVID-19 vaccine, due for precautionary dose OR Participant who have history of allergic reaction to first and/or second dose of COVID-19 vaccine.(Any one of these criteria should be satisfied) Participant of either gender of more than 18 years. Participants who are able to provide a written informed consent or have a legally accepted representative [LAR] to provide the same.

Exclusion criteria

Exclusion criteria: Participants who are participating in any other clinical trial or experimental treatment for COVID-19. Participants who are not deemed fit as per the investigator or his/her team for any other medical reason. Female participants who are pregnant or lactating.

Design outcomes

Primary

MeasureTime frame
Proportion of participants with negative skin test with both COVISHIELD vaccine, Polysorbate 80 and/or PEG among the total number of participants. Proportion of participants with negative skin test with COVISHIELD vaccine and positive with Polysorbate 80 and/or PEG among the total number of participants.Timepoint: Day Zero

Secondary

MeasureTime frame
Occurrence of unsolicited and solicited local and systemic adverse events after each dose of vaccine. Occurrence of unsolicited and solicited serious adverse events after each dose of vaccine. Timepoint: 6 to 8 hours and 72 hours after each dose of vaccine.

Countries

India

Contacts

Public ContactDr Dhruve Soni

Seth GS Medical College & KEM Hospital, Parel, Mumbai-400012

sonidhruve@gmail.com8894411660

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026